Drug Discovery and Development, Third Edition presents up-to-date scientific information for maximizing the ability of a multidisciplinary research team to discover and bring new drugs to the marketplace. It explores many scientific advances in new drug discovery and development for areas such as screening technologies, biotechnology approaches, and evaluation of efficacy and safety of drug candidates through preclinical testing. This book also greatly expands the focus on the clinical pharmacology, regulatory, and business aspects of bringing new drugs to the market and offers coverage of essential topics for companies involved in drug development. Historical perspectives and predicted trends are also provided.
Highlights emerging scientific fields relevant to drug discovery such as the microbiome, nanotechnology, and cancer immunotherapy; and novel research tools such as CRISPR and DNA-encoded libraries
Case study detailing the discovery of the anti-cancer drug, lorlatinib
Venture capitalist commentary on trends and best practices in drug discovery and development
Comprehensive review of regulations and their impact on drug development, highlighting special populations, orphan drugs, and pharmaceutical compounding
Multidiscipline functioning of an Academic Research Enterprise, plus a chapter on Ethical Concerns in Research
Contributions by 70+ experts from industry and academia specialists who developed and are practitioners of the science and business
Reviewer: Rahmat M. Talukder, PhD, RPh (The University of Texas at Tyler)
Description: Written by a strong team of scientists, this is the third edition of a book that provides up-to-date information on the scientific and regulatory aspects of drug discovery and development. Emerging technology and useful scientific tools in drug discovery are appropriately discussed.
Purpose: Drug discovery and development is a complex endeavor that requires a multidisciplinary team that has to have a comprehensive understanding of available tools and technology and relevant regulatory aspects for optimum utilization of resources in discovery and development.
Audience: The audience is scientists working in drug discovery and development. Because of the advances in technology and scientific tools available to the pharmaceutical industry, this book has been useful to its audience. This updated edition also should be useful for anyone interested in working in these areas. More than 70 experts have contributed up-to-date information on pertinent topics. The authors are well-known scientists in their respective fields.
Features: The first section offers a general overview of the evolution of, and innovation and challenges in, drug discovery and development. The next section explores the emerging science and technology related to drug discovery. For example, the applications of DNA-encoded library and CRISPR, a gene editing tool, to drug discovery are discussed well in one chapter. Another chapter presents a case study on the discovery and development of lorlatinib, an anti-cancer drug. That chapter also discusses the challenges associated with the scale-up of the synthesis of macromolecules. Another chapter describes the importance of the high-throughput screening process and how it can decrease the overall cost of drug discovery. Moreover, this section focuses on the potential use of microbiome and prodrugs as drugs and the use of nanotechnology for theranostic purposes. Section three presents the challenges and opportunities in the drug development process. A chapter that includes a table with examples of applications of PK-PD modeling discusses the integration of PK-PD principles in drug development. To assess the possible adverse effects of a drug candidate and, thus, to prevent the failure of the drug, one chapter discusses the importance of pharmacological profiling in drug discovery and development. Section four describes the regulatory aspects related to drug discovery and development. One chapter concisely presents the orphan drug approval process in the U.S., Europe, Australia, and Japan. There is evidence that many pharmacist-compounded products have become commercially manufactured products after their approval by regulatory agencies. Thus, a well-written chapter on compounding regulation has been added included in this section. This book could be enriched with more case studies, keywords at the beginning of each chapter, and a glossary of common terms.
Assessment: This third edition, written by experts from around the world, is expected to be useful for scientists working in this field. Each team in the drug discovery and development group will find some useful information in this book. There are many books in this area, but this one appears to discuss the topics in a bit greater detail.
– Doody’s Review Service